Results 101 to 110 of about 30,845,260 (288)

Cognitive Behavioral Therapy for Binge‐Eating Disorder in Individuals With Type 2 Diabetes: A Pilot Randomized Controlled Trial

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective To evaluate the feasibility of a randomized pilot trial of group‐based cognitive behavioral therapy (CBT) for binge eating disorder (BED) in individuals with type 2 diabetes, and to estimate exploratory clinical outcomes to inform the design of a future efficacy trial. Method Thirty‐four participants with type 2 diabetes and BED were
Pernille Fiil Nybo, Michael Einar Røder, Mia Beck Lichtenstein, René Klinkby Støving, Jakob Linnet   +4 more
wiley   +1 more source

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

Drug Design, Development and Therapy
Zhao Liu,1 Shanshan Yu,1 Xinyan Jin,1 Luguang Sheng,2 Mai Re YanMu,1 Jie Gao,1 Jun Lu,1 Tao Lei1 1Department of Endocrinology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of ...
Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T   +7 more
doaj  

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice

Pharmaceuticals
Background/Objectives: Type 2 diabetes and weight loss are associated with detrimental skeletal health. Incretin-based therapies (GLP-1 receptor agonists, and dual GIP/GLP-1 receptor agonists) are used clinically to treat diabetes and obesity.
Fang Lv, Xiaoling Cai, Chu Lin, Wenjia Yang, Linong Ji   +4 more
doaj   +1 more source

GLP-1 receptor agonists

, 2020
The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4.
openaire   +1 more source

Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?

Introduction Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-like peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD and are being considered for the treatment of PD.
Doggrell, Sheila A
core   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration

Biomolecules
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity.
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, David Tweedie, Nigel H. Greig   +4 more
doaj   +1 more source

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review [PDF]

Kathryn Haran,1 Chandler E Johnson,1 Payton Smith,1 Zoë Venable,2 Allison Kranyak,1 Tina Bhutani,1 Caleb Jeon,2 Wilson Liao1,3 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Department of Dermatology, Golden ...
Smith P, Johnson CE, Jeon C, Liao W, Kranyak A, Haran K, Venable Z, Bhutani T   +7 more
core  

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations [PDF]

Nimet Yılmaz,1 Mehmet Bastemir2 1Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey; 2Department of Endocrinology, SANKO University Faculty of Medicine, Gaziantep, TurkeyCorrespondence: Nimet Y&inodot ...
Bastemir M, Yılmaz N
core